Falcon Point Capital LLC lessened its stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 5.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 316,706 shares of the specialty pharmaceutical company’s stock after selling 18,953 shares during the quarter. Supernus Pharmaceuticals makes up approximately 2.1% of Falcon Point Capital LLC’s investment portfolio, making the stock its 19th largest position. Falcon Point Capital LLC’s holdings in Supernus Pharmaceuticals were worth $12,621,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SUPN. Northern Trust Corp boosted its holdings in shares of Supernus Pharmaceuticals by 2.8% in the 2nd quarter. Northern Trust Corp now owns 653,262 shares of the specialty pharmaceutical company’s stock valued at $28,155,000 after buying an additional 17,836 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 39.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after buying an additional 984,200 shares during the last quarter. M&T Bank Corp acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $213,000. Advisor Group Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 13.7% in the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after buying an additional 410 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Supernus Pharmaceuticals by 10.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock valued at $54,654,000 after buying an additional 122,042 shares during the last quarter. 98.20% of the stock is owned by institutional investors.
Shares of Supernus Pharmaceuticals Inc (SUPN) opened at $38.65 on Tuesday. Supernus Pharmaceuticals Inc has a twelve month low of $24.65 and a twelve month high of $50.04. The stock has a market capitalization of $1,906.95, a price-to-earnings ratio of 36.46 and a beta of 1.08.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. The company’s quarterly revenue was up 41.5% compared to the same quarter last year. equities research analysts predict that Supernus Pharmaceuticals Inc will post 1.07 earnings per share for the current year.
SUPN has been the subject of several recent analyst reports. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 10th. FBR & Co initiated coverage on Supernus Pharmaceuticals in a report on Thursday, October 19th. They issued a “buy” rating and a $53.00 price objective for the company. Janney Montgomery Scott raised Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Monday, December 4th. B. Riley increased their price objective on Supernus Pharmaceuticals from $50.00 to $54.00 and gave the company a “buy” rating in a report on Thursday, December 28th. Finally, Stifel Nicolaus raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Tuesday, November 7th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $51.36.
In other Supernus Pharmaceuticals news, VP Victor Vaughn sold 55,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $40.11, for a total transaction of $2,206,050.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $43.56, for a total value of $2,178,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 165,750 shares of company stock valued at $7,133,973 in the last ninety days. Insiders own 6.70% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.